PMID- 22360654
OWN - NLM
STAT- MEDLINE
DCOM- 20120601
LR  - 20191210
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 157
IP  - 3
DP  - 2012 May
TI  - Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular 
      lymphocyte-predominant Hodgkin lymphoma.
PG  - 321-30
LID - 10.1111/j.1365-2141.2012.09067.x [doi]
AB  - The pathological background in nodular lymphocyte predominant Hodgkin lymphoma 
      (NLPHL) consists of lymphocytes and histocytes. This study analysed the 
      peripheral blood absolute lymphocyte count/absolute monocyte count ratio at 
      diagnosis (ALC/AMC-DX) on the impact of survival in NLPHL. One hundred and three 
      consecutive NLPHL patients that were followed at Mayo Clinic from 1974 to 2010 
      were included in the study. Receiver operating characteristic and area under the 
      curve were used for ALC/AMC-DX cut-off value analysis and proportional-hazards 
      models were used to compare survival based on the ALC/AMC-DX ratio. With a median 
      follow-up of 8.9 years (range: 0.3-31 years), an ALC/AMC-DX >/=2.1 was the best 
      cut-off value for survival with an area under the curve of 0.82, a sensitivity of 
      70% and specificity of 84%. After adjusting for the International Prognostic 
      Score (IPS), ALC/AMC-DX remained an independent prognostic factor for overall 
      survival [Hazard Ratio (HR), 0.33, 95% confidence interval (CI), 0.15-0.71%, P < 
      0.004]; lymphoma-specific survival (HR, 0.05; 95%CI, 0.01-0.68%, P < 0.002); 
      progression-free survival (HR, 0.30; 95%CI, 0.14-0.60%, P < 0.006), and time to 
      progression (HR, 0.06, 95%CI, 0.04-0.30%, P < 0.004). ALC/AMC-DX is a low cost, 
      already standarized, biomarker to predict clinical outcomes in NLPHL.
CI  - (c) 2012 Blackwell Publishing Ltd.
FAU - Porrata, Luis F
AU  - Porrata LF
AD  - Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, 
      USA. porrata.luis@mayo.edu
FAU - Ristow, Kay
AU  - Ristow K
FAU - Habermann, Thomas M
AU  - Habermann TM
FAU - Witzig, Thomas E
AU  - Witzig TE
FAU - Colgan, Joseph P
AU  - Colgan JP
FAU - Inwards, David J
AU  - Inwards DJ
FAU - Ansell, Stephen M
AU  - Ansell SM
FAU - Micallef, Ivana N
AU  - Micallef IN
FAU - Johnston, Patrick B
AU  - Johnston PB
FAU - Nowakowski, Grzegorz S
AU  - Nowakowski GS
FAU - Thompson, Carrie
AU  - Thompson C
FAU - Markovic, Svetomir N
AU  - Markovic SN
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20120224
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - False Positive Reactions
MH  - Female
MH  - Hodgkin Disease/*blood/pathology/therapy
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Leukocyte Count
MH  - Lymphocyte Count
MH  - Lymphocytes/*pathology
MH  - Male
MH  - Middle Aged
MH  - Monocytes/*pathology
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Retrospective Studies
MH  - Sensitivity and Specificity
MH  - Young Adult
EDAT- 2012/03/01 06:00
MHDA- 2012/06/02 06:00
CRDT- 2012/02/25 06:00
PHST- 2011/11/09 00:00 [received]
PHST- 2012/01/18 00:00 [accepted]
PHST- 2012/02/25 06:00 [entrez]
PHST- 2012/03/01 06:00 [pubmed]
PHST- 2012/06/02 06:00 [medline]
AID - 10.1111/j.1365-2141.2012.09067.x [doi]
PST - ppublish
SO  - Br J Haematol. 2012 May;157(3):321-30. doi: 10.1111/j.1365-2141.2012.09067.x. 
      Epub 2012 Feb 24.